Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Key Highlights
- ➤Phathom (PHAT) will present three new VOQUEZNA GERD analyses at ACG 2026.
- ➤VOQUEZNA analyses cover BMI-stratified efficacy, real-world patient characteristics, and cost-effectiveness versus PPIs.
- ➤Phathom will host a VOQUEZNA Product Theater on clinical efficacy and safety.
- ➤VOQUEZNA is indicated for erosive GERD healing, maintenance, and non-erosive GERD heartburn relief.
Expert Statements
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“ACG provides an important opportunity to continue advancing the scientific dialogue around GERD and share new insights with the GI community”
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“These analyses add to the growing body of data on VOQUEZNA and provide new perspectives relevant to its use in GERD.”
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“We look forward to discussing these findings with GI healthcare providers and hearing firsthand perspectives from clinicians and patients throughout the meeting.”
* Three scientific presentations will highlight new analyses of VOQUEZNA(®) (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.
Phathom will present three scientific posters featuring new data and analyses for VOQUEZNA(®) (vonoprazan) in Gastroesophageal Reflux Disease (GERD), including a post hoc analysis of VOQUEZNA efficacy in patients with Non-Erosive GERD across Body Mass Index (BMI) subgroups, a retrospective analysis of real-world patient characteristics, and a model examining the cost-effectiveness of VOQUEZNA compared with proton pump inhibitors (PPIs) in Erosive Esophagitis, or Erosive GERD. The Company will also host a Product Theater to highlight the clinical efficacy and safety profile of VOQUEZNA.
Get started
Create a free account to read the full story.